Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab vs Pembrolizumab in 1L Metastatic Non-squamous NSCLC with STK11, KEAP1, or KRAS Mutations
NCT06008093Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival at 48 months, Progression-free survival at 6 months and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06008093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008093.